深圳普门科技股份有限公司 2025年度"提质增效重回报"行动方案 的半年度评估报告 为深入贯彻落实《关于开展沪市公司"提质增效重回报"专项行动的倡议》 的相关要求，积极践行"以投资者为本"的发展理念，维护深圳普门科技股份有 限公司（以下简称"公司"或"普门科技"）全体股东利益，公司结合自身发展 战略和经营情况，于2025年4月制定并披露了《2025年度"提质增效重回报"行 动方案》（以下简称"《行动方案》"）。2025年上半年，公司根据《行动方案》 积极落实相关举措并认真评估实施效果，《行动方案》半年度实施情况具体如下： 一、聚焦做强主业，提升核心竞争力 2025年上半年，尽管面临诸多外部挑战，公司聚焦体外诊断、治疗与康复两 大主业，秉承"质量•效率•积累•求变"四大核心经营理念，围绕全年的经营目 标，在新产品研发、市场渠道建设、产业规划布局等方面取得积极进展，整体经 营态势平稳有序。报告期内，公司实现营业收入50,684.91万元，实现归属于母公 司所有者的净利润12,157.59万元。 在产品研发方面，公司始终坚持以客户需求为导向开发与拓展产品，持续加 大研发投入力度，积极探索前沿技术路径，以保持在体外诊 ...

Core Viewpoint - The company is actively engaging in academic collaborations with well-known hospitals and universities in China to establish a market-oriented industry-university-research cooperation model, which lays a solid foundation for the rapid industrialization of new products [1] Group 1 - The company collaborates with notable institutions such as the Chinese People's Liberation Army General Hospital (301 Hospital), Chongqing University, Shandong University, and Shenzhen University [1]

Market Overview - The electronic chemicals sector experienced a decline of 0.53% on August 26, with Tongyu New Materials leading the drop [1] - The Shanghai Composite Index closed at 3868.38, down 0.39%, while the Shenzhen Component Index closed at 12473.17, up 0.26% [1] Stock Performance - Notable gainers in the electronic chemicals sector included: - Sanfu New Materials (688389) with a closing price of 73.20, up 10.46% [1] - Fivotech (688371) with a closing price of 23.27, up 6.35% [1] - Anji Technology (610889) with a closing price of 166.40, up 4.41% [1] - Conversely, significant decliners included: - Tongyu New Materials (301630) with a closing price of 199.23, down 8.75% [2] - Siquan New Materials (301489) with a closing price of 175.16, down 8.29% [2] - Shanghai Xinyang (300236) with a closing price of 53.75, down 3.98% [2] Capital Flow - The electronic chemicals sector saw a net outflow of 786 million yuan from institutional investors, while retail investors contributed a net inflow of 623 million yuan [2] - The capital flow for specific stocks showed: - Fivotech (688371) had a net inflow of 35.21 million yuan from institutional investors [3] - Anji Technology (610889) had a net inflow of 20.25 million yuan from institutional investors [3] - Tongyu New Materials (301630) experienced a significant net outflow of 49.42 million yuan from institutional investors [3]

证券代码：688389 证券简称：普门科技 公告编号：2025-064 深圳普门科技股份有限公司 关于召开2025年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 会议召开时间：2025年9月2日（星期二）上午10:00-11:00 ● 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） ● 会议召开方式：上证路演中心网络互动 ● 投资者可于2025年8月26日（星期二）至9月1日（星期一）16:00前登录 上证路演中心网站首页点击"提问预征集"栏目或通过深圳普门科技股份有限公 司（以下简称"公司"）邮箱bod@lifotronic.com进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 （三）会议召开方式：上证路演中心网络互动 三、参加人员 公司董事长刘先成先生，董事、总经理胡明龙先生，董事、副总经理曾映先 生，董事、财务总监王红女士，独立董事蔡翘梧先生、杨光辉 ...

深圳普门科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于近期收到了1个广东省 药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》， 具体情况如下： 证券代码：688389 证券简称：普门科技 公告编号：2025-063 上述注册证的取得仅代表公司相关产品获得国内市场准入资格，产品上市后 的实际销售情况取决于未来市场的推广效果，目前尚无法预测上述产品对公司未 1 / 2 来业绩的具体影响。 敬请投资者理性投资，注意投资风险。 特此公告。 深圳普门科技股份有限公司董事会 一、医疗器械注册证的具体情况 | 产品名称 | 注册 | 注册证 | 注册证 | | 预期用途 | | --- | --- | --- | --- | --- | --- | | | 分类 | 编号 | 有效期至 | | | | β-人绒毛膜促性腺激素 （β-HCG | | 粤械注准 | | 年 | 用于体外定量测定人血清或血 浆中β-人绒毛 ...

Policy Developments - The National Health Commission and five other departments released measures to enhance the experience of family doctor contract services, focusing on improving service quality and health management for residents [2] Drug and Device Approvals - Novo Nordisk's Wegovy (semaglutide 2.4mg) received FDA approval for treating metabolic-associated fatty liver disease (MASH) with moderate to severe liver fibrosis, which is expected to boost sales [3] - Yiling Pharmaceutical's new traditional Chinese medicine, "Children's Lianhua Qinggan Granules," has received acceptance for its new drug registration application [4] - Pumen Technology obtained a medical device registration certificate for its high-sensitivity cardiac troponin I testing kit, which aids in diagnosing myocardial infarction [5] Financial Reports - Ping An Good Doctor reported a 19.5% increase in revenue to approximately 2.502 billion yuan and a net profit increase of 136.8% to 134 million yuan for the first half of the year [6] - Weier Pharmaceutical's revenue decreased by 2.1% to 674 million yuan, with a net profit decline of 7.77% to 72.77 million yuan in the same period [7] Capital Market Activities - Jianzhijia plans to sell its Qinhuangdao logistics center assets for approximately 24 million yuan, which does not constitute a related party transaction [8] - Gilead Sciences announced a placement of 52.4 million shares at a discount of about 9.9%, with expected net proceeds of approximately 467.69 million HKD, primarily for clinical trials related to obesity [9] Industry News - The National Disease Control Bureau reported a decline in new cases of Chikungunya fever in Foshan, with daily cases dropping from over 600 to below 100, indicating effective control measures [10] - A breakthrough study from Harvard University demonstrated the ability to induce human pluripotent stem cells to initiate meiosis, offering new hope for addressing infertility [11] Public Sentiment Alerts - Baiotai announced that Xinyu Qiheng reduced its stake by 0.78%, selling 3.2169 million shares and raising approximately 105 million yuan [12]

Group 1 - The core point of the article highlights that Pumen Technology's stock price decreased by 0.75% on August 19, closing at 14.49 yuan, with a total market capitalization of 6.209 billion yuan [1] - The company's main business is medical device manufacturing, with its medical device segment accounting for 98.56% of revenue in the 2024 financial report [1] - In the first quarter of 2025, the company achieved operating revenue of 215 million yuan and a net profit of 53.68 million yuan [1] Group 2 - On August 19, the company announced it received a medical device registration certificate from the Guangdong Provincial Drug Administration for its high-sensitivity cardiac troponin I assay kit, which uses electrochemical luminescence to detect myocardial injury markers [1] - The stock experienced a net outflow of 13.52 million yuan from main funds on the same day, with a cumulative net outflow of 23.95 million yuan over the past five days [1]

Core Viewpoint - Pumen Technology has received a medical device registration certificate for its high-sensitivity cardiac troponin I (hs-cTnISTAT) assay kit from the Guangdong Provincial Drug Administration [1] Company Summary - The product is classified as an in vitro diagnostic reagent and utilizes electrochemical luminescence technology [1]

Group 1 - Pumen Technology (SH 688389, closing price: 14.49 yuan) announced on August 19 that it has received a Medical Device Registration Certificate from the Guangdong Provincial Drug Administration for its product "High-Sensitivity Cardiac Troponin I Test Kit" [2] - For the year 2024, Pumen Technology's revenue composition is as follows: 98.56% from medical devices and 1.44% from other businesses [2]

证券代码：688389 证券简称：普门科技 公告编号：2025-062 深圳普门科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于近期收到了1个广东省 药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》， 具体情况如下： 一、医疗器械注册证的具体情况 | 产品名称 | | | | | 注册 | 注册证 | 注册证 | | 预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 分类 | 编号 | 有效期至 | | | | 高 敏 心 肌 （hs-cTnI STAT）测定试 | 肌 | 钙 | 蛋 | 白 I | 类 II | 粤械注准 | 2030 | 年 | 用于体外定量测定人血清或血 浆中肌钙蛋白 （I cTnI）的含量。 | | | | | | | | 20252401126 | 月 日 8 | ...